Search

Your search keyword '"Eren Dağlar, Duygu"' showing total 5 results
Start Over Author "Eren Dağlar, Duygu" Language turkish
5 results on '"Eren Dağlar, Duygu"'

2. Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results

Author

Karataylı, Ersin, Soydemir, Ege, Aksoy, Zeynep Büşra, Kızılpınar, Mehtap, Altay Koçak, Aylin, Karataylı, Senem Ceren, Yurdcu, Esra, Yıldırım, Umut, Güriz, Haluk, Bozdayı, Gülendam, Yurdaydın, Cihan, İlhan, Osman, Yıldırım, Yasin, Bozdayı, A. Mithat, Yalçıntaş Oğuz, Açelya, Barış, Ahmet, Alp, Alpaslan, Aksözek, Alper, Sayıner, Arzu, Karagül, Aydan, Ordu, Aylin, İstanbullu, Ayşe, Otlu, Barış, Arıdoğan, Buket, Aksu, Burak, Buruk, C. Kurtuluş, Karahan, Ceren, Güney, Çakır, Toksöz, Devrim, Yıldırım, Dilara, Çolak, Dilek, Eren Dağlar, Duygu, Fındık, Duygu, Kaş, Elif, Çalışkan, Emel, Zeyrek, Fadile Yıldız, Arslan, Fatma, Demir, Feyza, Milletli, Fikriye, Kibar, Filiz, Özdinçer, Furkan, Dündar, Gülnur, Arslan, Hande, Ağca, Harun, Alışkan, Hikmet Eda, Güdücüoğlu, Hüseyin, Fidan, Işıl, Akyar, Işın, Afşar, İlhan, Kaleli, İlknur, Dönmez, İsmail, Yanık, Kemalettin, Midilli, Kenan, Çubukçu, Kıvanç, Özdemir, Mehmet, Acar, Melek, Yalınay, Meltem, Kuşkucu, Mert Ahmet, Bakıcı, Mustafa Zahir, Aydın, Neriman, Yılmaz, Neziha, Çeken, Nihan, Ziyade, Nihan, Yılmaz, Nisel, Özgümüş, Osman Birol, Gitmişoğlu, Özlem, Demirgan, Recep, Keşli, Recep, Güçkan, Rıdvan, Sertoz, Ruchan, Akgün, Sadık, Aksaray, Sebahat, Bayık, Seyit Ahmet, Akçalı, Sinem, Gürcan, Şaban, Karslıgil, Tekin, Us, Tercan, Özekinci, Tuncer, Pılgır, Tülin, Aslan, Uğur, Dinç, Uğur, Say Coşkun, Umut Safiye, Çetinkol, Yeliz, Keskin, Yusuf, Ayaydın, Zeynep, and Aşçı Toraman, Zulal

Subjects
Viral Yük, HBV DNA, HCV RNA, Dış Kalite Kontrol, External Quality Control, Viral Load
Abstract

Ülkemizde, moleküler mikrobiyoloji tanı laboratuvarlarında yapılan HBV DNA ve HCV RNA viral yük saptama testlerinin ulusal bir dış kalite kontrol programında değerlendirilmesi amacıyla MOTAKK (Moleküler Tanıda Kalite Kontrol) Ulusal Programı başlatılmıştır. ISO 17043:2010 (Uygunluk değerlendirmesi- Yeterlilik deneyi için genel şartlar) standartlarına uyularak hazırlanan bu program, ülkemizde yapılan moleküler tanı testlerinin, daha standart ve doğru yapılmasına katkıda bulunarak, yurt dışından sağlanan dış kalite kontrol (DKK) programlarının yerini almayı amaçlamaktadır. Bu çalışmada, MOTAKK DKK Programı kapsamındaki HBV DNA ve HCV RNA viral yük 2015 ve 2016 sonuçlarının değerlendirilmesi amaçlanmıştır. Yapılan çağrılar MOTAKK web sayfası (www.motakk.org) üzerinden ilan edilmiştir. Web sayfası üzerinden kayıt olan katılımcı laboratuvarlara, 2015 ve 2016 yıllarında birer kalite kontrol paneli gönderilmiştir. Çevrimlerde kullanılan paneller, HBV, HCV, HIV, HAV, Parvovirüs B19 ve CMV serolojik belirteçleri negatif olan plazma ile dilüsyon yapılan değişik viral yüklere sahip örnekler ile hazırlanmış, negatif örneklerle beraber soğuk zincirde katılımcı laboratuvarlara ulaştırılmıştır. Laboratuvarlar ilgili testleri 2-3 hafta içerisinde sonuçlandırarak, MOTAKK web sayfasına sonuçlarını girmiştir. MOTAKK tarafından geliştirilen bir yazılım ile katılımcı laboratuvarların sonuçları ISO 13528’e uygun olarak analiz edilerek sonuç raporları oluşturulmuş ve web sayfasına yüklenerek katılımcılara iletilmiştir. Katılımcılar, çalışma sonucunu diğer laboratuvar sonuçları ile karşılaştırmalı olarak değerlendirme imkanına sahip olmuş ve referans değerlere ve ortalama sonuçla ilgili farklılıkları görerek kullandıkları testleri tekrar değerlendirmiştir. HBV DNA ve HCV RNA DKK programına, 2015-2016 yıllarında 70-73 laboratuvar katılmıştır. Katılımcılar, program araçlarına yüksek uyum göstererek kayıt, sonuç girme ve sonuç raporlarının alınmasını aksaksız olarak gerçekleştirmişlerdir. HBV panelinde; 2015 yılında katılımcı laboratuvarların %72.6-89.1’inin, 2016 yılında ise %84.7-90.3’ünün 1 standart sapma (SS) aralığında yer aldığı görülmüştür. HCV panelinde ise; katılımcıların %70.8-89.1’i 1 SS’de, ikinci çağrının yapıldığı 2016 yılında ise, %84.7-90.3’ünün 1 SS’nin içerisinde yer aldığı görülmüştür. Bu proje ile Türkiye’de HBV DNA ve HCV RNA ile ilgili ilk kez ulusal bir DKK programı hazırlanmış ve başarıyla uygulanmıştır. MOTAKK, DKK programı sonuç raporlarında sağlanan bilgiler, yurt dışından sağlanan kalite kontrol programı sonuç raporlarının sağladığı tüm bilgileri karşılamakta; ek olarak kullanılan teknolojilerin ve ticari ürünlerin sağlıklı karşılaştırmalarına olanak sağlamaktadır. MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load . The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports without problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.

Published
2018

4. [Investigation of the Clinical Significance of Anti-Dense Fine Speckled 70 (anti-DFS70) Autoantibody and Determination of Accompanying Pathologies].

Author

Çetin Duran A, Barut K, Duran A, and Eren Dağlar D

Subjects
Antibodies, Antinuclear, Autoantibodies, Female, Fluorescent Antibody Technique, Indirect, Humans, Male, Adaptor Proteins, Signal Transducing, Transcription Factors
Abstract

Autoantibodies targeting nuclear and cytoplasmic autoantigens are used as markers in the diagnosis and classification of systemic autoimmune rheumatic diseases (SARD). The dense fine speckled (DFS) pattern is characterized by the fine-granular fluorescence of the nuclei in the interphase and the metaphase chromatin. DFS70 antibodies have been reported in healthy individuals, various autoimmune disorders, infection, cancer and inflammatory conditions. But there is still lack of information about its clinical significance. This study aimed to investigate the clinical significance of anti-DFS70 autoantibodies and the determination of accompanying pathologies. A total of 5710 serum samples routinely requested for ANA screening were tested between 2017 and 2019. Antinuclear antibody (ANA) and dsDNA were performed by indirect immunofluorescence method (IIF) (Euroimmun, Germany). Immunoblot (IB) method was used for the extractable nuclear antigen profile (ENA) (Euroimmun, Germany). Demographic and clinical data, were investigated from the medical records. Among 5710 samples tested for ANA, 23.7% were ANA positive by IIF. Mean age of the patients were 47.9 and 79.5% were female. Only 8.1% of the study group had SARD. The frequency of DFS pattern by ANA-IIF was 6.0% (342/5710), (mean age ± SD= 44.4 ± 16.7, 88% female). DFS70 pattern-positive patients were sub-grouped according to their diagnosis. SARD were detected 10.8% (mean age ± SD= 55.12 ± 14.10) in DFS70 pattern positive patient group (RA 6.1%, SS 2.6%, SLE 0.9%, SSc 0.6%, UCTD 0.6%). Autoantibodies accompanying anti-DFS70 antibody were determined as Ro-52, SS-A, nucleosome, histone, AMA-M2, dsDNA, respectively. Non-SARD diseases were determined in 89.2% of the patients with positive DFS70 pattern. Non-SARD diseases were detected as musculoskeletal complaints (47.4%), other rheumatic diseases like fibromyalgia (14.3%), dermatological diseases (9.4%), gastrointestinal system diseases (5.6%), hematological disorders (3.8%), thyroid /parathyroid diseases (3.5%), allergic diseases (2.3%), neurological diseases (2.3%) and neoplasia (breast cancer) (0.6%). The anti-DFS70 autoantibody is widely used to exclude the diagnosis of SARD in the absence of concomitant SARD-related autoantibodies. It has been observed that anti-DFS70 autoantibody may be associated with non-SARD rheumatic diseases and in many diseases (dermatological, gastrointestinal system, hematological, thyroid diseases) related to other systems. Therefore it is essential to evaluate these pathologies in patients positive for anti-DFS70 antibodies.

Published
2021
Full Text
View/download PDF

5. [Determination of cytomegalovirus glycoprotein B genotypes in different geographical regions and different patient groups in Turkey].

Author

Eren Dağlar D, Öngüt G, Çolak D, Özkul A, Mutlu D, Zeytinoğlu A, Midilli K, Gökahmetoğlu S, Günseren F, Öğünç D, and Gültekin M

Subjects
Adolescent, Adult, Aged, Child, Child, Preschool, Cytomegalovirus genetics, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections virology, DNA, Viral analysis, DNA, Viral chemistry, Female, Genotype, Humans, Infant, Infant, Newborn, Male, Middle Aged, Phylogeny, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Pregnancy, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious virology, Turkey epidemiology, Young Adult, Cytomegalovirus classification, Cytomegalovirus Infections epidemiology, Viral Envelope Proteins genetics
Abstract

Cytomegalovirus (CMV), a common virus found all around the world, usually causes asymptomatic infections in immunocompetent hosts, however it may lead to serious complications in immunodeficient patients and in the fetus. CMV is divided into four genotypes according to the polymorphisms in UL55 gene that encodes for envelope glycoprotein B. Nucleotide polymorphisms of CMV gB gene can affect the cell tropism of the virus and host immune response and believed to have important changes in the pathogenesis of CMV. The aim of this study was to determine the gB genotypes of CMV isolates from different patient groups selected from different regions of Turkey. A total of 136 clinical specimens from patients (66 female, 70 male; age range: 0-65 years, mean age: 24.03 ± 17.17) who were diagnosed to have CMV infection by polymerase chain reaction (PCR) and/or antigenemia tests, between 2001-2014, in the medical school hospitals of Akdeniz, Ege, Istanbul Cerrahpasa and Erciyes Universities (located at Mediterranean, Aegean, northwest and central Anatolia regions, respectively), were included in the study. The patient group consisted of 80 renal transplant (RT) recipients, 35 stem cell transplant (SCT) recipients, 13 newborns, seven heart transplant (HT) recipients and one pregnant woman. CMV gB genotypes were determined by PCR-RFLP (restriction fragment length polymorphism) method, and DNA sequencing and phylogenetic analysis were performed for the randomly selected 15 isolates with different genotypes. Among 136 (135 plasma, 1 amnion fluid) samples, the most frequent genotype was gB1 (n= 44, 32.4%), followed by gB2 (n= 39, 28.6%), gB3 (n= 36, 26.5%) and gB4 (n= 8, 5.9%); however nine (6.6%) samples could not be genotyped. When analysis were interpreted according to the patient groups, it was determined that the genotypes in RT recipients were gB1 32.3%, gB2 28.7%, gB3 26.5% and gB4 5.9%; in SCT recipients gB1 34.3%, gB2 28.6%, gB3 22.9% and gB4 5.7%; in HT recipients gB3 57.1%, gB1 14.3% and gB2 14.3%; in newborns gB1 38.4%, gB3 30.8%, gB2 15.4% and gB4 7.7%, and gB2 genotype in the pregnant woman. As our study was a descriptive study to determine the genotypes of CMV gB, the relationship between the genotypes and the variants such as viral load, symptomatic disease and prognosis were not analyzed. As a result, the isolation of different gB genotypes in various case groups from four distinctive provinces, underlines the diversity of CMV gB genotypes in Turkey.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results